Myeloproliferative Neoplasms | Specialty

The myeloproliferative neoplasms condition center is a comprehensive resource for clinical news on myeloproliferative neoplasms. Read more at OncLive.

Divesiran Is Tolerable and Shows Positive Early Signals in Polycythemia Vera

February 26th 2025

The siRNA divesiran was well-tolerated and reduced the number of phlebotomies that were required in patients with polycythemia vera.

Ruxolitinib Plus SOC Prophylaxis Is Associated With Lower Rates of GVHD in Myelofibrosis

February 14th 2025

Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.

Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

February 13th 2025

The MANIFEST-2 trial showed that pelabresib/ruxolitinib led to greater spleen volume reduction and improved anemia vs ruxolitinib alone in myelofibrosis

MD Anderson Study Resumes With Seclidemstat/Azacitidine in MDS/CMML

February 7th 2025

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.

Dr Al Malki on Reducing Relapse Risk in Patients Undergoing Haplo-HSCT

February 7th 2025

Monzr M. Al Malki, MD, discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation.

Type II JAK Inhibitor AJ1-11095 Under Phase 1 Investigation in Myelofibrosis

February 5th 2025

AJ1-11095 is being evaluated in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia.

Rovadicitinib Shows Safety, Clinical Activity After Ruxolitinib Intolerance in Myelofibrosis

February 5th 2025

The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.

Dr Sekeres on the Association Between Smoking and Disease Progression in MDS

February 5th 2025

Mikkael A. Sekeres, MD, discusses the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes.

Second-Line Fedratinib Produces Early Platelet Count Improvements in Myelofibrosis

February 5th 2025

Fedratinib showed early improvements in platelet count in patients with myelofibrosis.

The Potential of Oral HMAs in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.

Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.

Other Potential Roles for Luspatercept in MDS And Beyond

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.

Long-Term Transfusion Independence Data for Luspatercept vs ESAs in Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.

Optimal Goals for Anemia and Transfusion Independence in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.

Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.

The Importance of Treating Anemia in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.

Other Notable Myelofibrosis Data From ASH 2024

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses other notable myelofibrosis data from the 2024 ASH Annual Meeting.

Data for Navtemadlin in Relapsed/Refractory Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses data from the BOREAS trial for navtemadlin in relapsed/refractory myelofibrosis.

PERSIST-2 Post Hoc OS Data for Pacritinib in Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses post hoc overall survival data for pacritinib in myelofibrosis.

The Relationship Between Thrombocytopenia/Anemia on Disease Progression in Myelofibrosis

January 31st 2025

Sangeetha Venugopal, MD, MS, discusses the relationship between thrombocytopenia and anemia on disease progression in myelofibrosis